Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgical procedure and Director of Spinal Surgical procedure on the Weill Cornell Mind and Backbone Middle in New York, and the co-director of New York-Presbyterian Och Backbone.
Dr. Hartl turns into Aclarion’s 2nd KOL to get entry to an MRI heart licensed to carry out Nociscans, including NYC to Denver because the second lively KOL website.
Aclarion will report on Nociscan volumes so far earlier than the top of the yr and add this key metric to quarterly reporting starting in 2024.
BROOMFIELD, CO, Nov. 06, 2023 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the situation of power low again ache, introduced as we speak that Roger Hartl, M.D., Hansen-MacDonald Professor of Neurological Surgical procedure and Director of Spinal Surgical procedure on the Weill Cornell Mind and Backbone Middle in New York, in addition to the co-director of New York-Presbyterian Och Backbone, will advise the corporate as a key opinion chief (KOL) nationally.
Dr. Hartl’s apply emphasizes an interdisciplinary method to illness processes, and he works very carefully with different specialists to personalize affected person remedies. “My medical curiosity focuses on easy and sophisticated spine surgical procedure for degenerative circumstances, in addition to organic approaches for disc restore and regeneration,” mentioned Dr. Hartl. “Aclarion’s expertise is addressing a significant hole in present diagnostics for discogenic low again ache. I count on Nociscan will present invaluable, goal data to our interdisciplinary method for treating degenerative disc illness. Moreover, I consider Nociscan shall be equally invaluable in our efforts to raised perceive much less invasive surgical and organic therapy methods for degenerative illnesses of the spine.”
Power low again ache (cLBP) is a number one explanation for opioid habit within the U.S. and the only costliest analysis in america. Aclarion’s Nociscan answer is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
“Dr. Hartl is a world-renowned neurosurgeon who continues to additional developments within the analysis and therapy of low again ache,” mentioned Brent Ness, CEO of Aclarion. “With quick entry to a Nociscan activated MRI on New York Metropolis’s Park Avenue, Dr. Hartl has already used Nociscan and can proceed to achieve medical insights into his sufferers’ circumstances properly into the long run.”
Over the previous 18 months, Aclarion has constructed a number one consortium of 10 KOL surgeons. Dr. Hartl represents the tenth and closing KOL addition to Aclarion’s panel. The Firm is now within the essential stage of activating MRIs for every of its KOLs to allow them to start utilizing the expertise, monitoring medical outcomes, and advocating for payer protection selections to develop entry to Nociscan to all sufferers. The Firm will announce extra MRI activations for the remaining KOLs as they grow to be out there and can start to report on scan volumes as Nociscan use grows with these MRI activations.
For details about Nociscan use in New York Metropolis, please contact Aclarion at firstname.lastname@example.org.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By means of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
This press launch incorporates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, corresponding to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to assessment the part titled “Threat Components” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Change Fee on April 25, 2022 underneath Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.